Infant Bacterial Therapeutics is listed on Nasdaq First North and publishes company description
March 21, 2016

Infant Bacterial Therapeutics AB (publ) (“IBT”) has been approved for listing and the company’s series B shares will be traded on Nasdaq First North as from 29 March 2016 with Erik Penser Bankaktiebolag as Certified Adviser. The listing is part of the distribution of all of BioGaia AB’s (publ) shares in IBT to BioGaia’s shareholders, which was resolved at the extraordinary general meeting of BioGaia on 18 March 2016.


A company description has been prepared in connection with the listing and is available on IBT’s website,



For additional information please contact

Staffan Strömberg, CEO, phone: +46 8 410 145 55


Infant Bacterial Therapeutics AB

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55


See Press Release in both Swedish and English:

IBT Press Release 20160321 (Swedish)

IBT Press Release 20160321 (English)